A Multicenter, Double Blind, Placebo Controlled, Randomized Study of TroVax vs. Placebo in the First Line Treatment of Patients with Metastatic Colorectal Cancer Receiving Standard of Care.

Trial Profile

A Multicenter, Double Blind, Placebo Controlled, Randomized Study of TroVax vs. Placebo in the First Line Treatment of Patients with Metastatic Colorectal Cancer Receiving Standard of Care.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2012

At a glance

  • Drugs MVA 5T4 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FLAMENCO
  • Most Recent Events

    • 07 Jul 2012 Planned number of patients changed from 1300 to 1312 and addtional trial location (United Kingdom) added as reported by European Clinical Trials Database record.
    • 20 Jun 2012 Actual initiation date (11 Jul 2008) and trial location (Spain) added as reported by European Clinical Trials Database record.
    • 20 Jun 2012 Actual end date (31 Oct 2009) added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top